Eckert & Ziegler SEXTER:EUZ -1.03%98 Net Margin % is 14.22% as of Mar. 2026, which is 22% above its 10-year median of 11.67. GuruFocus rates XTER:EUZ with a GF Score™ of 98/100 and a GF Value™ of €16.25 (Fairly Valued). Among 817 Medical Devices & Instruments companies, Eckert & Ziegler SE ranks better than 82.86% on this metric.
The historical rank and industry rank for Eckert & Ziegler SE's Net Margin % or its related term are showing as below:
XTER:EUZ'
s Net Margin % Range Over the Past 10 Years
Min: 7.97 Med: 11.67 Max: 19.14
Current: 15.61
XTER:EUZ's Net Margin % is ranked better than 82.86% of 817
companies
in the Medical Devices & Instruments industry
Industry Median: 2.09
vs XTER:EUZ: 15.61
Eckert & Ziegler SE (XTER:EUZ) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Eckert & Ziegler SE Net Margin % Related Terms
Eckert & Ziegler SE Net Margin % Historical Data
* Premium members only.
The historical data trend for Eckert & Ziegler SE's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XTER:EUZ vs ABT, SYK, MDT: Net Margin % Comparison
For the Medical Devices subindustry, Eckert & Ziegler SE's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Eckert & Ziegler SE Net Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Eckert & Ziegler SE's Net Margin % distribution charts can be found below:
* The bar in red indicates where Eckert & Ziegler SE's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Eckert & Ziegler SE (XTER:EUZ) has a Net Margin % of 14.22% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Eckert & Ziegler SE and its competitors. This is 22% above median its historical median of 11.67. Over the past decade, Eckert & Ziegler SE's Net Margin % has ranged from 7.97 to 19.14. According to the industry distribution chart, Eckert & Ziegler SE ranks #140 out of 817 companies in the Medical Devices & Instruments industry, placing it in the top 17.1%.
Is Eckert & Ziegler SE's Net Margin % too high?
Eckert & Ziegler SE's current Net Margin % of 14.22% is 22% above median its 10-year median of 11.67. Over the past 10 years, this metric has ranged from a low of 7.97 to a high of 19.14. The Medical Devices & Instruments industry median Net Margin % is 2.09. Eckert & Ziegler SE's value of 14.22% is 580.4% above this industry median. Based on the distribution chart, Eckert & Ziegler SE ranks #140 out of 817 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Eckert & Ziegler SE has a GF Score™ of 98/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Eckert & Ziegler SE's Net Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Eckert & Ziegler SE ranks #140 out of 817 companies for Net Margin %. This places Eckert & Ziegler SE in the top 17% of its industry — outperforming the majority of peers. The industry median Net Margin % is 2.09. Eckert & Ziegler SE's value of 14.22% is 580.4% above this benchmark. Historically, Eckert & Ziegler SE's own Net Margin % has ranged from 7.97 to 19.14 over the past decade. While the company's 10-year median is 11.67 vs. the industry median of 2.09, Eckert & Ziegler SE has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Medical Devices & Instruments company?
The median Net Margin % among Medical Devices & Instruments companies is 2.09, based on 817 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Eckert & Ziegler SE's current Net Margin % of 14.22% is 580.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Eckert & Ziegler SE and its competitors. For the Medical Devices & Instruments industry, the median Net Margin % is 2.09 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Eckert & Ziegler SE's current Net Margin % is 14.22%, which is 22% above median its own 10-year median of 11.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eckert & Ziegler SE stock overvalued right now?
Based on GuruFocus' analysis, Eckert & Ziegler SE (XTER:EUZ) is currently considered Fairly Valued. The stock's GF Value™ is €16.25, compared to a current price of €15.41 — trading 5.2% below its estimated fair value. The current Net Margin % is 14.22%, which is 22% above median its 10-year median of 11.67 and 580.4% above the Medical Devices & Instruments industry median of 2.09. Eckert & Ziegler SE's overall GF Score™ is 98/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Eckert & Ziegler SE (XTER:EUZ), the current Net Margin % is 14.22% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Eckert & Ziegler SE (XTER:EUZ) Overvalued in 2026?
Based on GuruFocus' analysis, Eckert & Ziegler SE stock appears to be undervalued.
The current stock price of €15.41 is trading 5.2% below its estimated GF Value™ of €16.25.
GuruFocus considers Eckert & Ziegler SE to be Fairly Valued.
Key valuation signals for XTER:EUZ:
Net Margin %: 14.22% (22% above median its 10-year median of 11.67)
GF Value™: €16.25 vs. price of €15.41 (5.2% below fair value)
Industry Position: 580.4% above the Medical Devices & Instruments median (#140 of 817)
No single metric tells the full story. See the XTER:EUZ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Eckert & Ziegler SE is a holding company with specialised in the processing of radioisotopes and the development, production and sale of isotope technology components, radiopharmaceuticals and related products. It is an international manufacturer of isotope technology components for medical, scientific, and industrial applications. The group's products are mainly used in cancer therapy, nuclear imaging, and industrial metrology. The company's segments are Medical, Isotope Products, and Other. The majority of revenue comes from Medical segment which provides pharmaceutical-quality radioactive ingredients and markets products for the treatment and diagnosis of cancers. Geographically, the company generates a majority of its revenue from Europe and then North America, Asia/Pacific, and other.
98GF Score
Get the complete analysis for XTER:EUZ
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XTER:EUZ has been successfully added to your 
